“There is power struggle as well as ideological struggle in the government”

S Srinivasan, managing trustee of LOCOST, shares why the NITI Aayog should not interfere with the price control of essential drugs and why the government is so apathetic to healthcare concerns

kaushal

Kaushal Shroff | December 21, 2016 | New Delhi


#drug regulation   #WHO   #chemists   #drug pricing   #healthcare   #medicines  
S Srinivasan, Managing Trustee, LOCOST
S Srinivasan, Managing Trustee, LOCOST


S Srinivasan is the managing trustee of LOCOST, a charitable trust involved with the production of low-priced quality generics for over 32 years. He has also been active in works like transfer of pharmaceutical technology to least developed countries, issues of disadvantaged children and human rights, and relief in disaster situations. In a one-on-one with Kaushal Shroff, he shares why the Niti Aayog should not interfere with the price control of essential drugs and why the government is so apathetic to healthcare concerns.


News reports suggest that the government is considering reducing the number of price controlled drugs under the DPCO. Apparently, Niti Aayog has written to the health ministry asking it to remove all “regulatory hurdles”. How do you perceive this move?

There are different ideologies working within the government and they are at loggerheads with each other. Niti Aayog was basically lobbied by some pharma companies from Mumbai and they convinced them that price control is bad for the pharma industry. I don’t think it is a concerted, well thought-out statement from Niti Aayog. The arm of the government which should actually be talking about this issue is the department of pharmaceuticals or the body which actually administers the DPCO, i.e., the National Pharmaceutical Pricing Authority. The NPPA is very keen on administering the DPCO but certain sections of the department of pharmaceuticals want to free up the market [from regulations], so they lobby or try to work on some of these people who are for freeing the market. Otherwise, Niti Aayog has no business saying it.

Also, the Indian Pharmaceutical Alliance has been losing some cases in the courts relating to DPCO, so they are getting desperate. Actually, there is no need for them to get desperate because price control, as it is today, covers only 10-15 percent of the market. The total domestic market is about Rs 1 lakh crore and an equal amount is of the exports. So, what is Rs 10-15 thousand crore? Nothing. It is just a way of making a lot of noise, creating scare tactics so that no one raises questions against pharma [companies] because we [the companies] are contributing to the nation.

Whatever little price control is there, it has been achieved after a lot of fight. Because of people like us [civil society] who are putting pressure through the supreme court. The attitude of the government is that we will do it [enforce price control] just because the SC is asking us to do so. There is a power struggle as well as an ideological struggle going on in the government.

If any instrument affects only 10-15 percent of the market, how can it be detrimental? Every year, 90 percent of the drugs which are not under price control are allowed to increase their prices by 10 percent as per DPCO. Whereas drugs under price control are allowed to increase only as per the wholesale price index. The policy needs to be a bit thorough; it is very badly thought-out that way.


READ: High Dose: How your medicine bill is likely to shoot up


In 2003, you along with other petitioners moved the SC seeking a change to the pharmaceutical pricing policy so that essential medicines come within the grasp of the poor. Subsequently, the government came out with a model that seems to make drugs even more expensive. Do you foresee a possibility of going back to the cost-based pricing method or is it a closed chapter now?

It is not a closed chapter. It is one of the issues before the SC. As far as petitioners like us continue, it is not a closed chapter. Market-based pricing is nonsense. It is not used anywhere in the world in any sector.
Any attempt at price control will have to reduce price. Whatever formula you use – market based or cost based – if it has got some honest aim, it should show that it is controlling prices. In the market-based method, the price of the costliest drug of a particular brand will come down because you have to take a simple average. If the costliest brand is selling at Rs 100 and then there are brands selling at Rs 10, 20, 30, 40 and so on, then you take an average and the 100 will have to come down. So that way prices have decreased but even then in many cases, because of the way the price band is located, structured or placed out in the market, most of the brands are priced towards the higher level. The price in the market-based pricing system is not near the cost. That is why we are against this market-based pricing. It doesn’t reflect cost. There are a lot of brands in the market that are selling at 2,000-3,000 percent margin. One can take an average but even then the ceiling price will be 1,000 percent more than the cost price.

 

Comments

 

Other News

How to leverage AI to solve urgent global issues

The world seems to be hurling towards World War III in all the possible scenarios: hot war, cold war, and proxy war. The battleground seems to have expanded beyond physical to digital or virtual/mixed reality with technology like drones. Moreover, the line between civilian and military targets seems to hav

Budget: Progress towards SDGs and areas for improvement

The Union Budget 2025-26 outlines India`s vision for economic and social growth while also reflecting the country`s commitment to sustainable development. As India moves closer to the 2030 deadline for the United Nations’ Sustainable Development Goals (SDGs), this budget presents a balanced approach

Repo rate cut by 25 basis points to 6.25%

The Reserve Bank of India has, for the first time in five years, reduced the policy repo rate under the liquidity adjustment facility (LAF) by 25 basis points to 6.25% with immediate effect. Consequently, the standing deposit facility (SDF) rate will stand adjusted to 6.00% and the marginal

Amitav Ghosh’s new work: Connections between the word and the world

Wild Fictions: Essays By Amitav Ghosh HarperCollins, 496 pages, Rs 799.00 Amitav Ghosh, one of a handful of Ind

How markets can help (and also hinder) fight against pollution

In the annals of environmental policy, few ideas have been as transformative as the Emissions Trading System (ETS). Born from the minds of economists in the late 1960s, this market-based approach to pollution control has evolved from a theoretical concept to a global tool in the fight against climate chang

Will Bihar complement the resolution of Viksit Bharat 2047?

As India completes its diamond jubilee as a republic, I am reminded of a statement by Dr. A.P.J. Abdul Kalam, delivered during an address to the Bihar Chamber of Commerce in Patna on March 28, 2006. He said, “I have visited Bihar numerous times, and it has always been a source of happiness for me to

Visionary Talk: Amitabh Gupta, Pune Police Commissioner with Kailashnath Adhikari, MD, Governance Now



Archives

Current Issue

Opinion

Facebook Twitter Google Plus Linkedin Subscribe Newsletter

Twitter